How does trastuzumab emtansine's patent expiry affect drug prices?

When does trastuzumab emtansine’s patent (and related exclusivity) end, and why pricing changes follow

Trastuzumab emtansine is an antibody-drug conjugate (ADC) marketed in the EU/US as Kadcyla. Patent expiry matters because it removes legal barriers that can keep competitors from launching “generic” or next-best versions with the same active ingredient and dosing approach. Once key exclusivities end (patents and other protections such as supplementary protection certificates, where applicable), manufacturers can seek regulatory approval and launch competing products. That typically shifts the market from protected pricing toward competition, which often lowers acquisition prices and can also increase use of lower-cost options through payer contracting.

DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, including trastuzumab emtansine, which can be used to estimate when price pressure is most likely to begin. [1]

What happens to the price after patent expiry: expected direction, but not an immediate free fall

Even after patent expiry, the price response depends on what competition actually arrives. In many oncology markets, patent expiry leads to:
- Lower “net” prices over time as payers negotiate discounts with the original manufacturer.
- Formulary pressure that rewards cheaper competing products or biosimilar-like alternatives, where they are available.
- Slower declines than people expect when the only “competition” is from manufacturer copay programs, fewer launch entrants, or products that are not fully interchangeable.

For trastuzumab emtansine specifically, the practical effect is most often seen in payer contracting rather than a sudden sticker-price cut. The originator company may cut prices to keep share once competitor entry becomes realistic.

Does “patent expiry” automatically mean generics or biosimilars can enter?

Not necessarily. For biologic and ADC medicines, “follow-on” options may not be true generics, and what can launch depends on:
- Which patents are still active (process, formulation, method-of-use, combination claims, etc.).
- Whether regulators require clinical data for “similar” products.
- How “design-around” competitors are able to avoid remaining claims.

That means pricing pressure can be delayed if competitors face overlapping patent thickets or if litigation keeps alternative launches off the market. DrugPatentWatch.com’s patent timelines can help identify whether exclusivity ends cleanly or whether other protections likely extend the window. [1]

How litigation and “at-risk” launches can change the timing of price competition

If competitors plan to launch near the end of a patent term, they may trigger patent challenges or settlements that can:
- Delay entry (extended exclusivity in effect),
- Bring entry later than the earliest theoretical expiry date, or
- Produce a “launch window” that starts pricing pressure abruptly once a court settlement or final regulatory approval clears the way.

So, drug prices often start moving around the first actual competitive launch, not the earliest patent expiry date alone.

What to watch for with payers and hospitals after expiry

After key protections end for trastuzumab emtansine, the clearest signals that prices are shifting are usually:
- Contracting updates (new preferred product status and revised discount tiers).
- Changes in prior authorization and step therapy rules.
- Increased uptake of any lower-cost alternative ADCs (or other trastuzumab-based options, if clinically appropriate).

If no credible competitor launches, prices may stay relatively stable and payer discounts may be modest.

Where to find the patent-expiry timeline used to forecast price impact

For a drug-by-drug view of patent and exclusivity status, DrugPatentWatch.com provides searchable patent information and expiry-related details for trastuzumab emtansine. [1]

Sources
[1] https://www.drugpatentwatch.com/